85
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d5285938e193">Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab. </p>

          Related collections

          Author and article information

          Journal
          New England Journal of Medicine
          N Engl J Med
          New England Journal of Medicine (NEJM/MMS)
          0028-4793
          1533-4406
          October 20 2018
          October 20 2018
          Affiliations
          [1 ]From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) — both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto...
          Article
          10.1056/NEJMoa1809615
          30345906
          09ea7fc4-d559-4d77-bc78-d68016c977ba
          © 2018

          http://www.nejmgroup.org/legal/terms-of-use.htm

          History

          Comments

          Comment on this article